Showing results (1191-1200 of 1,547) with videos related to
Sort By:
Pageof 155
Neuro-Oncology|January 9, 2022
Liquid biopsy in gliomas: A RANO review and proposals for clinical applicationsRiccardo Soffietti, Chetan Bettegowda, Ingo K Mellinghoff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.Journal for Immunotherapy of Cancer|July 3, 2021
Systematic review of combinations of targeted or immunotherapy in advanced solid tumorsAaron C Tan, Stephen J Bagley, Patrick Y Wen, et al.The Journal of Hospital Infection|June 5, 2024
Adherence to guidelines and central-line-associated bloodstream infection occurrence during insertion and maintenance of intravascular catheters: evidence from 20 tertiary hospitalsF Zang, J Liu, Y Wen, et al.JCO Precision Oncology|September 11, 2020
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With GlioblastomaBrian M Alexander, Lorenzo Trippa, Sarah Gaffey, et al.Neuro-Oncology|January 17, 2019
Advances in multidisciplinary therapy for meningiomasPriscilla K Brastianos, Evanthia Galanis, Nicholas Butowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyTimothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.Journal of Neuro-Oncology|October 13, 2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiformeMorris D Groves, Vinay K Puduvalli, Susan M Chang, et al.Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.Pageof 155